Sanofi Ventures has assembled a team of individuals combining not only investor backgrounds but also entrepreneurial experiences in biotech companies.


Bernard Davitian
SVP and Managing Director


Bernard Davitian is a successful biotech entrepreneur with extensive experience in financings and M&A marked by the IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.

Bernard joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development and was promoted to Vice President and Managing Director of Sanofi Ventures in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP, COO & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.

Bernard currently serves on the Board of Directors for Lysosomal Therapeutics and Click Therapeutics. In addition, he is a board observer for Yumanity Therapeutics and Evidation Health.

Bernard holds a MSc in Management (MBA equivalent) from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from the Wharton school of Business.

Jason P. Hafler
US head of investments


Jason joined Sanofi Ventures in 2014 with a background in early stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at RaNA Therapeutics, LLC a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group and a Board Observer for several portfolio companies. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason currently serves on the Board of Directors for Expansion Therapeutics and is a board observer for Navitor Pharmaceuticals and Kymera Therapeutics. In addition, he is on the Board of Directors for a Sanofi Ventures-backed seed stage company. Jason also serves on the Board of Trustees at the Buckingham Browne and Nichols school, the Board of Directors of The Magdalene College Foundation and the Board of Directors of the Beacon Hill Nursery School.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Ruchita Sinha
Senior Director of Investments


Ruchita joined Sanofi Ventures in 2016 with a relevant background in digital health. Prior to Sanofi, Ruchita was at GE Ventures, where she invested in and built partnerships with healthcare startups and served as a board observer for several portfolio companies. Ruchita also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and healthcare IT. Prior to GE Ventures, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company.

Ruchita is currently a board observer for Inozyme and Omada Health.

Ruchita holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Christopher Gagliardi
Director of Investments


Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at LEK consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.

Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a BS in both Biology and Chemistry from Roger Williams University.

Daniel Mansuri
Associate Director


Daniel joined Sanofi Ventures in 2018. He began his career as a member of Biogen's corporate strategy group. He then joined Bioverativ as a member of their BD organization, most recently as Business Development Lead, where he played an important role in both their acquisition of True North Therapeutics and their research collaboration with Bicycle Therapeutics. Given the recent acquisition, we are fortunate to benefit from Daniel’s expertise in the rare hematology and complement space.

Daniel graduated with honors from Bates College with a Bachelor of Science in Economics and a minor in Chemistry.

Laia Crespo
EU Head, Sanofi Ventures


Laia joined Sanofi Ventures in 2018 with a background in biotech investing primarily in Europe. Prior to Sanofi, Laia served as Investment Director for Ysios Capital, a Venture fund based in Barcelona, where she led investments and served on the Boards of OxThera (Sweden), Minoryx Therapeutics (Spain) and Inbiomotion (Spain), and as an Observer with AM-Pharma (The Netherlands). Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a PhD with honors. Laia holds an MBA from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

Robin Smick
Executive Assistant


Robin joined Sanofi Ventures in 2018 with a background in administrative medical affairs at Sanofi since 2013. Prior to Sanofi, Robin was the Head of Administration at MIT Bates Research & Engineering Center for five years. Robin also spent 10 years conducting property and business valuations for variety of companies.

Robin studied Business administration and finance at Salem State University.